Please rate the following questions:
Overall quality of the meeting.
Please rate how well the following objectives were met:
Discuss basic aspects of alloimmunity and antigen processing.
Describe measures to prevent post transplant malignancies.
Describe how to develop a relationship with a referring physician.
Describe how pre-transplantation eradication of hepatitis C may effectively prevent post-
transplantation recurrence of disease.
Discuss the current and upcoming research being conducted at the US Department of Health and
Human Services, Organ Procurement and Transplant Network, and developing partnerships with
other government organizations.
Describe new immunosuppressive agents in kidney transplantation currently in clinical trials.
List the gold-standard techniques for measurement of GFR and their surrogate markers.
Please rate how well the following objective was met:
Describe the role of the alloantibody response in clinical transplantation.
Discuss the effect of mTOR inhibition on vascular cell injury and repair.
List the types of infections transmitted with organs to recipients.
Identify and discuss pancreas transplant categories.
Discuss current issues in Antibody crossmatching.
Discuss Immunologic Monitoring and if the practices and procedures are ready to be used more
widely.
Discuss the new practices of Gene Silencing And Conditional Gene Expression.
List and discuss the functional and phenotypic characteristics of NK and NKT cells.
Discuss the Challenges and Opportunities in Composite Tissue Allografts.
Discuss the long-term impediments to quality of life in patients undergoing liver transplantation in
adults and pediatrics recipients.
Provide five reasons for incorporating recommendations and encouragement for physical activity
following organ transplant.
Discuss whether Solid Organ Transplant Recipients should receive New Interventions For The
Metabolic Syndrome
Discuss the new practice of Pulsatile Perfusion Of Donor Organs.
Discuss top abstracts presented.
Please rate how well the following objective was met.
Discuss potential controversial areas of donor evaluation and recipient selection in living donor
liver transplantation.
Identify what constitutes a nanotherapeutic.
Discuss the field of T cell-mediated suppression.
Cite new and current practices to deal with Ischemia reperfusion injury.
Identify the risk factors associated with Hepatocellular Carcinoma.
List reasons for the high incidence of cancer.
Summarize differences between innate and adaptive immunity.
Discuss molecular aspects of the mTOR pathway and why mTOR inhibitors could be useful in the
prevention and treatment of malignancies that develop, especially in transplant recipients.
Discuss Therapeutic Prospects of Alternate Co-stimulation Pathways.
Discuss the role of dendritic cells in allorecognition.
Discuss the function and problems encountered with Memory T Cells.
Discuss new problems and therapies associated with extended donors in liver transplantation.
Identify appropriate allocation of liver and kidney for patients with combined disease.
Review the constructs that contribute to HRQOL.
Describe exchange donor transplantation programs in Korea and their results.
Identify the barriers to transplantation and review potential solutions.
Please rate how well the objective was met.
Discuss that biological processes are naturally controlled by microRNAs.
Discuss critical aspects of CKD, its incidence and prevalence.
Describe an experimental protocol that was used in an attempt to induce tolerance following
organ transplantation.
Discuss the current outcomes of liver transplantation for recipients with HCV.
Explain why individuals deficient in complement develop lupus.
Discuss inducing tolerance to organ transplants in children.
List the requirements for obtaining board certification.
Discuss the application of molecular markers to predict primary graft dysfunction after lung
transplantation.
Review Mechanistic Insights into Chronic Allograft Vasculopathy.
Review Therapeutic Potential of T Regulatory Cells.
Explain interactions between the innate and the adaptive immune systems.
Discuss problems and therapies used for Pregnancy after Transplantation.
Review MELD / PELD Inequities and how to improve MELD/PELD scores.
List vaccinations which should ideally be administered or updated before transplant.
Explain the role and value of rituximab.
Identify a complex of findings in patients who develop recurrence of diabetes following kidney-
pancreas transplant.
Cite the differences in access to transplantation and transplant outcomes between Canada and
United States.
Discuss the appropriate development of end points in clinical trials for heart transplantation.
Discuss the current evidence of virus-specific humoral and cellular immune markers in kidney
transplant patients at risk for polyomavirus BK-associated nephropathy.
Discuss using living donors for liver transplantation.
Review excepted practices of Xenotransplantation.
Discuss ideas on B Cells and how they stop graft acceptance.
Describe the role of chemokines in directing T cells and other leukocyte populations to grafts and
ischemic tissues.
Discuss the outcomes following heart retransplantation and define predictors of a poor outcome
following heart retransplantation.
Discuss Non-medical Causes of Renal Allograft Loss.
Discuss rationales for variations in intestinal transplantation, i.e. inclusion of other organs.
Describe how to treat Parasitic infections in Transplant Recipients and Donors.
Identify diseases that recur post-transplantation.
Review new practices discussed throughout the ATC.
Explain the common mechanisms contributing to graft injury.
Describe the effects of diabetes on grafts, hepatitis C infection, immunosuppression and the effect of insulin on the liver.
Discuss the need for waitlist management in liver transplantation including regulatory aspects, medical and clinical review of patients on the liver transplantation waiting list.
Identify the limitations of HCV treatment in the liver transplant patient awaiting transplantation.
Discuss the increasing proportion of the kidney wait list that is inactive.
Identify what recipient factors can maximize donor outcome.
Evaluate potential therapies for transplantation in the sensitized patient.
If you answered any of the above questions with 'Below Average' or 'Poor,' please explain:
Discuss lineage, phenotype, and function of T-regs.
Discuss current immunosuppression drugs, upcoming immunosuppressive drugs, and how to ease patients into immune tolerance.
List methods used to monitor patients listed and waiting for kidney transplant.
List the benefits of induction therapy in patients with HCV infection.
List achievable donor management targets.
Discuss a critical definition of tolerance.
How can this training be improved to impact your competence or practice?
Define clinical features associated with tolerance.
Discuss acceptance criteria, waitlist management, DCD donors and high risk patients in liver, kidney and thoracic transplantation.
Cite the factors associated with worse outcomes following OLT for patients with HCV infection.
Additional comments: